AlphaQuest LLC Purchases 6,265 Shares of Danaher Corporation $DHR

Key Points

• AlphaQuest LLC significantly increased its holdings in Danaher Corporation by 3,797%, owning 6,430 shares worth approximately $1.32 million as of the end of the first quarter.
• Danaher reported a quarterly EPS of $1.80, exceeding analysts' estimates, with revenue of $5.94 billion, showing a year-over-year increase of 3.4%.
• Seventeen research analysts currently rate Danaher stock as a "Moderate Buy" with a consensus price target of $247.61.

AlphaQuest LLC increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 3,797.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,430 shares of the conglomerate's stock after purchasing an additional 6,265 shares during the quarter. AlphaQuest LLC's holdings in Danaher were worth $1,318,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of DHR. Bank Pictet & Cie Europe AG increased its stake in Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after purchasing an additional 35,730 shares in the last quarter. First Trust Advisors LP increased its stake in Danaher by 13.6% in the 4th quarter. First Trust Advisors LP now owns 37,854 shares of the conglomerate's stock worth $8,689,000 after purchasing an additional 4,519 shares in the last quarter. MGO One Seven LLC increased its stake in Danaher by 1.3% in the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock worth $984,000 after purchasing an additional 53 shares in the last quarter. Capital Analysts LLC increased its stake in Danaher by 8.0% in the 4th quarter. Capital Analysts LLC now owns 17,258 shares of the conglomerate's stock worth $3,961,000 after purchasing an additional 1,273 shares in the last quarter. Finally, Wills Financial Group Inc. grew its stake in Danaher by 1.4% during the 4th quarter. Wills Financial Group Inc. now owns 41,797 shares of the conglomerate's stock valued at $9,594,000 after acquiring an additional 578 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

DHR has been the topic of several research analyst reports. Robert W. Baird lifted their target price on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Wells Fargo & Company lowered their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Danaher Stock Performance

Danaher stock traded down $1.29 during trading hours on Wednesday, reaching $204.96. 2,503,235 shares of the company were exchanged, compared to its average volume of 4,195,627. The firm has a market cap of $146.76 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.90 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average of $201.02 and a 200 day moving average of $199.43. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.